

nerlynx[®]▼
(neratinib)

PHYSICIAN TREATMENT GUIDE

A therapy management guide to help support your patients receiving NERLYNX (neratinib)

NERLYNX is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab based therapy less than one year ago¹



▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may experience via the national reporting system (Appendix V - European Medicines Agency - Europa EU) and/or to the Pharmacovigilance department of Pierre Fabre laboratories (www.pierre-fabre.com/en/pharmacovigilance)

This material is based on EU Product Information and does not replace the SmPC and the RMP Educational Materials. Please refer to the material approved in your country.


Pierre Fabre

CONTENTS

1. About NERLYNX	2
2. NERLYNX administration	3
3. Adverse events management	5
4. Proactive management of diarrhoea	7
5. Management of hepatotoxicity	10
6. Contraindications	11
7. Interactions	12
8. Patient dialogue is key	13

References:

1. Nerlynx (neratinib 40 mg film-coated tablets) Summary of Product Characteristics. Last update 2022.
2. Pernas S and Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. *Ther Adv Med Oncol.* 2019;11:1-16.
3. Cameron D, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the Herceptin Adjuvant (HERA) trial. *Lancet.* 2017;389:1195-205.
4. Piccart-Gebhart MJ, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. *N Engl J Med.* 2005;353(16):1659-1672.
5. Chan A, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2016;17:367-77.
6. Martin M, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2017;18(12):1688-1700.
7. Feldinger K and Kong A. Profile of neratinib and its potential in the treatment of breast cancer. *Breast Cancer: Targets and Therapy.* 2015;7:147-162.
8. Collins DM, et al. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer. *Cancers.* 2019;11, 737; doi:10.3390/cancers11060737.
9. Rabindran SK, et al. Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase. *Cancer Res.* 2004;64(11):3958-3965.
10. Canonici A, et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. *Oncotarget.* 2013;4:1592-1605.
11. Wissner A and Mansour TS. The Development of HKI-272 and Related Compounds for the Treatment of Cancer. *Arch Pharm Chem Life Sci.* 2008;34:465-477.
12. Pinter M, et al. Cancer and liver cirrhosis: implications on prognosis and management. *ESMO Open.* 2016;1(2)e000042. eCollection 2016.
13. European Medicines Agency Public Assessment Report (EPAR). Nerlynx EMA/CHMP/525204/2018.
14. Chan A, et al. Effect of prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2-positive early stage breast cancer: phase II CONTROL trial. Poster P5-14-03 presented at SABCS 2019.
15. Mortimer J, et al. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial. *Breast Cancer Res.* 2019;21(1):32. Electronic Supplementary Material.
16. Cancer.Net. Doctor-Approved Patient Information from ASCO on Diarrhea. Available at: <https://www.cancer.net/coping-with-cancer/physical-emotional-and-social-effects-cancer/managing-physical-side-effects/diarrhea>. Accessed: June 2020.
17. National Cancer Institute. Diarrhea and Cancer Treatment. Available at: <https://www.cancer.gov/about-cancer/treatment/side-effects/diarrhea>. Accessed: June 2020.
18. Jenkins M, et al. Patient perspectives on HER2+ breast cancer recurrence: results from an online patient survey. *Cancer Res.* 2019;79 (4 Suppl):Abstract nr P5-14-03.

1 ABOUT NERLYNX


1.1 What is NERLYNX?

For nearly 20 years, patients with HER2+ breast cancer have benefited from the addition of trastuzumab-based therapy to chemotherapy.^{2,3} However, up to 31% face a disease-free survival event within 10 years after treatment.^{3,4} Is there more that can be done to further reduce the risk of recurrence for HER2+/HR+ breast cancer after trastuzumab-based therapy?

NERLYNX is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.¹

Following adjuvant trastuzumab-based therapy, NERLYNX, as extended adjuvant therapy, offers an additional step up in the treatment of HER2+/HR+ breast cancer.^{1,5,6}

Introducing NERLYNX as extended adjuvant therapy




1.2 How does NERLYNX work?

NERLYNX is a tyrosine kinase inhibitor (TKI) that penetrates the cell membrane to target the intracellular domain of the HER receptors, HER1, HER2 and HER4.^{7,8}

As a targeted therapy, NERLYNX limits damage to healthy cells, as its activity is focused on the receptors involved in HER2+ breast cancer.^{7,8}

NERLYNX irreversibly binds to the tyrosine kinase domains of HER receptors, resulting in pan-HER signalling inhibition. The sustained inhibition of the HER2 downstream signalling inhibits tumour cell proliferation and increases cell death.⁷⁻¹¹



2 NERLYNX ADMINISTRATION

2.1 General population

NERLYNX is an oral, once-daily therapy¹

 NERLYNX does not require any special temperature storage conditions.¹

 NERLYNX is to be taken at approximately the same time, preferably in the morning, every day.¹

 If a dose is missed or vomited, NERLYNX is to be resumed the next day.¹

 Tablets should be swallowed whole, and should not be crushed or dissolved.¹

 Grapefruit and pomegranate in any form should be avoided.¹

2.2 Specific populations

Dose adjustments

Elderly¹

- No dose adjustment is required.
- There is no data in patients ≥85 years of age.

Renal impairment¹

- No dose adjustment is required for patients with mild to moderate renal impairment.
- NERLYNX has not been studied in patients with severe renal impairment (eGFR ≤29 mL/min/1.73 m²) including patients on dialysis. Treatment is not recommended.

Hepatic impairment¹

- No dose adjustment is required for patients with Child-Pugh A or B (mild to moderate).
- Treatment of patients with Child-Pugh C hepatic impairment is not recommended.

Child-Pugh score¹²

Variable	Points		
	1	2	3
Hepatic encephalopathy	None	Stage I-II	Stage III-IV
Acites	Absent	Controlled	Refractory
Bilirubin (mg/dL)	<2	2-3	>3
Albumin (g/L)	>35	28-35	<28
Prothrombin time (seconds)	<4	4-6	>6

Prognostic sub-group¹²

Sum of points	5-6	7-9	10-15
Class	A (mild)	B (moderate)	C (severe)

Pregnancy, lactation & contraception¹

There are no data from the use of NERLYNX in pregnant women, therefore, NERLYNX should not be used during pregnancy. Women of child-bearing potential must use highly effective contraceptive measures while taking NERLYNX and for 1 month after stopping treatment.¹

It is not known whether NERLYNX is excreted in human milk. A risk to the breast-fed infant cannot be excluded. A decision must be made whether to discontinue breast-feeding or NERLYNX.¹

eGFR, estimated glomerular filtration rate.

3.1 Adverse events¹

System organ class	Adverse reaction	All grades (%)	≥ Grade 3 (%)
General disorders	Fatigue	27.3	-
Metabolic and nutritional disorders	Decreased appetite	13.7	-
Hepatobiliary disorders	ALT increase	8.5	1.3
	AST increase	7.4	0.7
Gastrointestinal disorders	Diarrhoea	93.6	37.1
	Nausea	42.5	-
	Abdominal pain*	35.9	-
	Vomiting	26.8	3.5
	Stomatitis	11.2	-
Skin and subcutaneous tissue disorders	Rash	15.4	0.4
	Nail disorders	7.8	0.2
Musculoskeletal and connective tissue disorders	Muscle spasms	10.0	-


Table adapted from Nerlynx SmPC.

ALT, alanine aminotransferase; AST, aspartate aminotransferase.

*Includes abdominal pain and abdominal pain upper.


The addition of antidiarrhoeal prophylaxis to NERLYNX treatment decreased the severity and duration of diarrhoea.^{13,14}

Median cumulative duration of diarrhoea (days) for the whole treatment period¹³



3.2 Recommended dose adjustments for adverse event management


Management of some adverse reactions may require dose interruption and/or dose reduction. Adjusting daily dose can improve tolerability and adherence.^{1,14}



Management according to the severity of adverse reactions and based on individual safety and tolerability¹

General adverse events¹

(See pages 8 and 10 for specific management of diarrhoea and hepatotoxicity.)





4.1 Antidiarrhoeal prophylaxis while on NERLYNX^{1,14}

Start your patients on antidiarrhoeal prophylaxis with the first dose of NERLYNX and continue for the first 1-2 months of NERLYNX therapy to decrease the severity, incidence and duration of diarrhoea.^{1,14}

Diarrhoea management with loperamide¹⁴

Time on NERLYNX	Loperamide dose	Frequency
Weeks 1-2 (days 1-14)	4 mg	Three times daily
Weeks 3-8 (days 15-56)	4 mg	Twice daily
Weeks 9-52 (days 57-365)	4 mg	As needed (not to exceed 16 mg per day)




4.2 Management according to the severity of diarrhoea¹⁵

The overall management of diarrhoea is based upon its grade as measured by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).¹⁵

NCI CTCAE: Grading for diarrhoea¹⁵

Grade 1	Increase of <4 stools per day over baseline Mild increase in ostomy output compared to baseline	
Grade 2	Increase of 4-6 stools per day over baseline Moderate increase in ostomy output compared to baseline	
Grade 3	Increase of ≥7 stools per day over baseline Incontinence, hospitalisation indicated; severe increase in ostomy output compared to baseline; limiting self-care activities of daily living (ADL)	
Grade 4	Life threatening consequences intervention indicated	Urgent

Dose adjustments according to the severity of diarrhoea and based on individual safety and tolerability¹⁴



*Complicated features include dehydration, fever, hypotension, renal failure, or Grade 3 or 4 neutropenia.
†Despite being treated with optimal medical therapy.

4.3 Helpful advice

Diet modifications

Patients should be instructed to adapt their diet in order to minimise diarrhoea.^{16,17}

Things to do:



Eat small, more frequent meals



Drink 8 to 10 large glasses (a total of ~2 liters) of clear liquids every day



Choose foods that are easy to digest (low-residue diet)

These include bananas, rice, applesauce and toast

Things to avoid:



Medicines such as laxatives or stool softeners



Caffeine, alcohol, dairy, fat, fibre, orange juice, grapefruit juice, pomegranate juice, prune juice, and spicy foods

Support materials

There are numbers of materials available for you and your patients to help support them throughout their treatment with NERLYNX:

The Health Care Professional Brochure, with information on measures to help reduce side effects.



The Patient Brochure and the Patient Treatment Guide, providing education to help prepare for treatment.



The Patient Treatment Diary, to monitor their daily symptoms, enabling treatment adjustments as needed.



5 MANAGEMENT OF HEPATOTOXICITY¹

Hepatotoxicity has been reported in patients treated with NERLYNX. Liver function tests including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin should be monitored at 1 week, then monthly for the first 3 months and every 6 weeks thereafter while on treatment or as clinically indicated.¹

Dose modifications for hepatotoxicity¹

Severity of hepatotoxicity*	Action
<ul style="list-style-type: none"> Grade 3 ALT (>5-20 x ULN) 	<ul style="list-style-type: none"> Stop NERLYNX until recovery to Grade 0-1
OR	<ul style="list-style-type: none"> Evaluate alternative causes
<ul style="list-style-type: none"> Grade 3 bilirubin (>3-10 x ULN) 	<ul style="list-style-type: none"> Resume NERLYNX at the next lowest level if recovery to Grade 0-1 occurs within 3 weeks. If Grade 3 ALT or bilirubin occurs again despite one dose reduction, permanently discontinue NERLYNX If Grade 3 hepatotoxicity persists longer than 3 weeks, discontinue NERLYNX permanently
<ul style="list-style-type: none"> Grade 4 ALT (>20 x ULN) 	<ul style="list-style-type: none"> Permanently discontinue NERLYNX
OR	<ul style="list-style-type: none"> Evaluate alternative causes
<ul style="list-style-type: none"> Grade 4 bilirubin (>10 x ULN) 	

ULN, Upper Limit Normal; ALT, Alanine Aminotransferase.
*Per CTCAE v4.0

6 CONTRAINDICATIONS¹

- Hypersensitivity to the active substance or to any of the excipients: mannitol (E421), microcrystalline cellulose, crospovidone, povidone, colloidal anhydrous silica, magnesium stearate, polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, iron oxide red (E172).
- Severe hepatic impairment (Child-Pugh C).

Other medicines

Contraindicated	Examples
Co-administration with strong inducers of the CYP3A4/Pgp isoform of cytochrome P450	<ul style="list-style-type: none"> carbamazepine, phenytoin (antiepileptics) St John's wort (<i>Hypericum perforatum</i>) (herbal product) rifampicin (antimycobacterial)

Medications	Considerations	Examples
Proton pump inhibitors, H2-receptor antagonists and antacids	<p>Co-administration with proton pump inhibitors (PPIs) is not recommended.</p> <p>If H2-receptor antagonists are used: NERLYNX should be taken at least 2 hours before or 10 hours after the intake of the H2-receptor antagonist.</p> <p>If antacids are taken: separate the dosing of NERLYNX and the antacid by at least 3 hours.</p>	omeprazole, lansoprazole, dexpanoprazole, rabeprazole, pantoprazole; nizatidine, famotidine, cimetidine or ranitidine
Strong or moderate CYP3A4/P-gp inhibitors	<p>Concomitant treatment is not recommended due to risk of increased exposure to NERLYNX.</p> <p>If the inhibitor cannot be avoided, reduce NERLYNX dose.</p>	atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, ketoconazole, itraconazole, clarithromycin, telithromycin, and voriconazole, grapefruit/ pomegranate or grapefruit/ pomegranate products
Moderate CYP3A4/P-gp inducers	Concurrent use of NERLYNX with moderate CYP3A4/P-gp is not recommended as it may lead to loss of efficacy.	bosentan, efavirenz, etravirine, phenobarbital, primidone or dexamethasone
Strong CYP3A4/P-gp inducers	Concurrent use with NERLYNX is contraindicated.	phenytoin, carbamazepine, rifampicin, or herbal preparations containing St John's Wort (<i>Hypericum perforatum</i>)
Breast cancer resistance protein efflux transporters	<p>NERLYNX may inhibit breast cancer resistance protein (BCRP) intestinal level as suggested by in vitro studies. Clinical studies with BCRP substrates have not been conducted.</p> <p>Patients who are treated with BCRP substrates should be monitored carefully.</p>	rosuvastatin, sulfasalazine or irinotecan
P-glycoprotein efflux transporters	<p>In in-vitro studies, NERLYNX is an inhibitor of P-glycoprotein (P-gp) efflux transporters. This might be clinically relevant for patients who are treated concomitantly with therapeutic agents with a narrow therapeutic window whose absorption involves P-gp transporters in the gastrointestinal tract.</p> <p>These patients should be carefully monitored.</p>	digoxin, colchicine, dabigatran, phenytoin, statins, cyclosporine, everolimus, sirolimus or tacrolimus

By integrating NERLYNX into your patients' treatment plan from the start, and explaining the importance of adherence, you can help your patient stick to their treatment and reduce their risk of recurrence.

Your support helps patients to be:¹⁸



More informed




More prepared



More supported

Make sure that you provide your patients with the Risk Management Plan (RMP) educational materials to help them to understand more about their treatment and how to be aware of, and minimise the risk of adverse events.



NERLYNX ABBREVIATED PRESCRIBING INFORMATION

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. See below for how to report any adverse events.

NAME OF THE MEDICINAL PRODUCT: Nerlynx 40 mg film-coated tablets.

CLINICAL PARTICULARS: **Therapeutic indications:** Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.

Posology and method of administration: Nerlynx treatment should be initiated and supervised by a physician experienced in the administration of anticancer medicinal products.

Posology: The recommended dose of Nerlynx is 240 mg (six 40 mg tablets) taken orally once daily, continuously for one year. Nerlynx should be taken with food, preferably in the morning. Patients should initiate treatment within 1 year after completion of trastuzumab therapy.

Dose modification: Nerlynx dose modification is recommended based on individual safety and tolerability. The management of adverse reactions may require dose reduction, temporary interruption or treatment discontinuation (For complete information, please refer to SmPC Section 4.2.)

Method of administration: Nerlynx is for oral use. The tablets should be swallowed whole preferably with water and should not be crushed or dissolved, and should be taken with food, preferably in the morning (see SmPC Section 5.2).

Contraindications: Hypersensitivity to the active substance or to any of the excipients listed in SmPC Section 6.1. Co-administration with strong inducers of the CYP3A4/Pgp isoform of cytochrome P450: Carbamazepine, phenytoin (antiepileptics), St John's wort (*Hypericum perforatum*) (herbal product), Rifampicin (antimycobacterial). Severe hepatic impairment (Child-Pugh C)(see section 5.2).

Special warnings and precautions for use: Diarrhoea. Patients with a significant chronic gastrointestinal disorder. Elderly patients. Patient with Renal impairment. Liver dysfunction. Left ventricular dysfunction. Pregnancy. Patients with symptomatic skin and subcutaneous tissue disorders. For complete information, please refer to SmPC Section 4.4.

Interaction with other medicinal products and other forms of interaction: Concomitant use of strong or moderate CYP3A4/Pgp inhibitors significantly increase neratinib exposure. CYP3A4/Pgp inducers significantly decrease neratinib exposure. Grapefruit/pomegranate or grapefruit/pomegranate juice should be avoided. For complete information, please refer to SmPC Section 4.5.

Contraceptives and breastfeeding: Women of child-bearing potential must use highly effective contraceptive measures while taking Nerlynx and for 1 month after stopping treatment. Men should use a barrier method of contraception during treatment and for 3 months after stopping treatment. It is not known whether Nerlynx is excreted in human milk. A risk to the breast-fed infant cannot be excluded. For complete information, please refer to SmPC Section 4.6.

Undesirable effects: Summary of safety profile: The most common adverse reactions of any grade were diarrhoea (93.6%), nausea (42.5%), fatigue (27.3%), vomiting (26.8%), abdominal pain (22.7%), rash (15.4%), decreased appetite (13.7%), abdominal pain upper (13.2%), stomatitis (11.2%), and muscle spasms (10.0%). For complete information, please refer to SmPC Section 4.8.

Overdose: There is no specific antidote, and the benefit of haemodialysis in the treatment of Nerlynx overdose is unknown. In the event of an overdose, administration should be withheld and general supportive measures undertaken. For complete information, please refer to SmPC Section 4.9.

MARKETING AUTHORISATION HOLDER : Pierre Fabre Médicament - Les Cauquillous, 81500 Lavaur, France.

DATE OF REVISION OF THE TEXT: March 2022. Detailed information on this medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu>.

For complete information, please refer to SmPC. Latest review of EU SmPC : 2022.

REPORTING OF SUSPECTED ADVERSE REACTIONS

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are requested to report any suspected adverse reactions via the national reporting system (Appendix V - European Medicines Agency - Europa EU) and/or to the Pharmacovigilance department of Pierre Fabre laboratories (www.pierre-fabre.com/en/pharmacovigilance)



For complete information, please refer to : NERLYNX
Summary of Product Characteristics
https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf